Discussing PepsiCo, Inc. (NASDAQ:PEP), Cramer said: “Yeah, Pepsi’s got, I mean, I read, I talked about that Cornell ... the company has lost market share to portfolio holding Eli Lilly due ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...

This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best big name stocks to invest in now. Big name stocks refer to well-known companies ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years for the Company.

Eli Lilly (NYSE ... at the low end of the company’s guidance range. It views 2025 guidance more positively, driven by GLP blockbusters Mounjaro and Zepbound. Eli Lilly is set to continue ramping ...